Welcome to the second segment of Big Health Talks, where we speak with clinical experts and benefits leaders about trends, challenges, and solutions in mental health care and the emerging field of digital therapeutics (DTx).
In this episode, Gabriela Perez, Chief Commercial Officer at Big Health, is joined by Cody Midlam, Director and Pharmacist Consultant at Willis Towers Watson. They discuss everything you need to know about DTx: the potential market, benefits, and predictions for the coming years.
How big is the potential market for DTx?
Where do you see DTx going in the next 2-3 years?
Who stands to benefit from the expansion of DTx, and how?
Subscribe today to receive updates from Big Health
Cody is a paid consultant for Big Health.
Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy.
DOC-2919 Effective 06/2023
Digital medicine, Mental health, Mental Health AwarenessShare article
About the Author
Your guide to understanding mental health terminology
It’s easy to become overwhelmed by the complex terminology used in the mental health space, so we’ve created a resource…
Blog/4 min read
Why is it so hard to find a therapist?
Therapists are in short supply, but it’s more complicated than that.
Blog/6 min read
Additive care options to antidepressants
Into the medicine cabinet: The reach of SSRIs and SNRIs
Blog/7 min read